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) mice do not exhibit delayed (late phase) protection from ischemia-reperfusion (I/R)-induced inflammation afforded by preconditioning with H 2 S or ethanol, whereas wild-type (WT) mice do (48, 49) . Moreover, HO-1 Ϫ/Ϫ mice have been reported to develop nitrate tolerance, which was associated with reduced levels of soluble guanylate cyclase (sGC) (20) . HO-1 is an inducible enzyme that conveys cytoprotection by producing biliverdin along with the products iron and carbon monoxide (45) . It has been proposed to play an important role in the antioxidant and anti-inflammatory activity associated with delayed preconditioning in WT mice (21, 22) . Indeed, a number of preconditioning strategies have been associated with increased levels of HO-1 protein during delayed or late-phase preconditioning (21, 48) . We proposed that an important component of that protection was related to HO-1 maintaining the heme iron of sGC in a reduced state (Fe 2ϩ ) that would retain sensitivity to nitric oxide (NO) (20) . In that study, we made use of two drugs: one that was a stimulator (BAY 41-2272) of reduced sGC and one that was a more effective activator (BAY 60-2770) of oxidized (heme-free) sGC (10, 24) . Superior mesenteric arteries (SMAs) from HO-1 Ϫ/Ϫ mice were more responsive to the sGC activator than those from WT mice (20) . This indicated that HO-1 Ϫ/Ϫ had more of sGC in an oxidized heme-free state, which would not be responsive to NO. It has been recognized that a number of agents that convey preconditioning protection to I/R injury act via the NO-cGMP-PKG pathway, with potassium channels [e.g., large-conductance Ca 2ϩ -activated K ϩ (BK Ca ) and ATP-sensitive K ϩ (K ATP ) channels] being downstream targets (8, 32, 38) . Therefore, one strategy to convey protection to I/R injury under conditions where sGC is compromised by oxidative stress (e.g., in HO-1 Ϫ/Ϫ mice) would be to precondition with an agent that would act preferentially on oxidized heme-free sGC.
This strategy has been tested in several studies that evaluated the effectiveness of cinaciquat as a cardioprotective agent during oxidative stress and I/R injury. Chronic treatment provided cardiopulmonary protection to fetal sheep exposed to intrauterine pulmonary hypertension (6) . Acute preconditioning before cardiopulmonary bypass in dogs led to improved recovery of cardiac contractility and coronary artery responses to ACh (35) . Acute preconditioning before coronary artery occlusion in rabbits and mice also significantly reduced infarct size after reperfusion (37) . In addition, cinaciquat reduced infarct size when given just before reperfusion (8, 37) . At that time, flow of oxygenated blood into ischemic tissue can lead to the production of ROS and damage including oxidation of heme in sGC (21) . Therefore, a sGC activator would be a rational choice to promote tissue protection under such conditions.
The above studies with sGC activators did not use conditions to determine whether delayed or late-phase preconditioning (e.g., 24 h before ischemia) can be induced by a sGC activator or a stimulator such as BAY 41-2272 and whether these compounds will inhibit inflammatory responses associated with I/R injury. It was our objective to determine whether preconditioning with BAY compounds 10 min (early phase) or 24 h (late phase) before I/R would convey protection from inflammation and retain responses to ACh in mesenteric vessels. We also evaluated the effectiveness of these compounds in HO-1 Ϫ/Ϫ mice that were susceptible to ROS damage, where sGC levels are reduced and nitrate tolerance develops with an associated reduction in responses to ACh (20) .
MATERIALS AND METHODS

Animals
WT H129 breeders and endothelial NO synthase (eNOS) knockout (eNOS Ϫ/Ϫ ) mice (C57BL/6 background) were purchased from The Jackson Laboratory (Bar Harbor, ME), whereas HO-1 Ϫ/Ϫ breeders (H129 background) were a gift from Dr. William Fay (University of Missouri, Columbia, MO). All of the female HO-1 Ϫ/Ϫ mice used in this study were bred in University of Missouri facilities and were used at 8 -12 wk of age. Genotyping was done on lysates from tail samples according to previously used methods (20) . Experimental procedures were performed in compliance with institutional guidelines for humane animal care and use and were approved by the Institutional Animal Care and Use Committee.
Surgical Procedures and Induction of I/R
The procedures were similar to those previously used in our laboratory to maintain continuity (16, 48, 49) . Mice were anesthetized with a mixture of ketamine (150 mg/kg body wt) and xylazine (7.5 mg/kg) followed by a midline abdominal incision. The SMA was identified and later occluded for 45 min [0 min for sham-operated (sham) mice]. The left jugular vein was cannulated for the administration of carboxyfluorescein diacetate succinimidyl ester (CFDASE; Molecular Probes, Eugene, OR) to label leukocytes after ischemia. CFDASE stock (5 mg/ml) was prepared by adding DMSO; the resulting solution was then aliquoted and stored in light-tight containers at Ϫ70°C until use. A 5-min infusion (20-fold dilution in saline) of the fluorescent probe allowed leukocyte-endothelial interactions to be observed via intravital fluorescence microscopy over minutes 30 -40 and 60 -70 of reperfusion.
Intravital Fluorescence Microscopy
Mice were placed on a Plexiglas board, and a section of the small intestine was exteriorized over a glass coverslip and superfused with a bicarbonate-buffered saline (37°C, pH 7.4). Body temperature was maintained between 36.5 and 37.5°C by means of a thermostatically controlled heat lamp. The Plexiglas board was mounted on the stage of an inverted microscope (Eclips TE2000, Nikon), and the intestinal microcirculation was observed through a ϫ20 objective lens. Fluorescent images (excitation: 420 -490 nm and emission: 520 nm) were detected with a charge-coupled device camera (Photometrics COOL-SNAP ES). Images were projected onto a television monitor (PVM-1953MD, Sony) and recorded on a DVD recorder (DMR-E50, Panasonic). A time-date generator (WJ810, Panasonic) displayed this function on the monitor.
The intestinal segment was scanned, and 10 single unbranched venules (diameter: 20 -50 m and length: 100 m) were observed for at least 30 s. Leukocyte-endothelial interactions (number of rolling leukocytes and number of firmly attached leukocytes) were quantified in each venule followed by calculation of the mean for 10 venules. Leukocytes were considered to be adherent if they did not move for at least 30 s. Rolling cells were defined to be those passing a cross line at a velocity significantly slower than the centerline velocity and are expressed as rolling cells per minute. Numbers of adherent cells were normalized in terms of millimeter squared surface area.
In Situ Experimental Protocols
The experimental design for each group is shown in Fig. 1 Group 5: paxilline ϩ BAY 60-2770 ϩ I/R. Mice received paxilline (2.5 mg/kg ip) 10 min before BAY 60-2770 (300 g/kg ip) 24 h before I/R. Paxilline was used to inhibit BK Ca channel activity, which has been associated with delayed protection to H 2S (49) .
Group 6: DL-propargylglycine ϩ BAY 60-2770 ϩ I/R. Mice received DL-propargylglycine (PAG; 50 mg/kg ip) 10 min before BAY 60-2770 (300 g/kg ip 24 h before I/R) and again 30 min before I/R. PAG was used to inhibit H2S production by cystathionine-␥-lyase (CSE), which has been associated with BAY 58-2667 preconditioning (37) .
Vascular Rings
After the in situ protocol, SMAs were removed, dissected free of surrounding tissue, and placed in ice-cold low-Ca 2ϩ (0.15 mM) physiological solution (PS). Arteries were trimmed free of fat and cut into rings ϳ0.5 mm long. The outside diameter (range: 400 -500 m) was measured with a calibrated reticle in the dissection microscope (SMZ-2B, Nikon). Rings were mounted on force transducers (FT03, Grass Instruments) that had specially fabricated feet with an open wire (diameter: 51 m) design. Rings were gently slipped onto the open end with the aid the microscope and stretched 1.2 times their resting diameter before being placed into PS (10 ml in plastic cups) at 36°C. Rings were tested with high K ϩ (K ϩ : 80 mM substituted for Na ϩ ) to establish a reference contracture and then returned to PS, relaxed, stretched 5%, and retested with high K ϩ and so forth. Rings were considered to be at or near the optimum length for force production when the 5% stretch produced a Ͻ10% increase in contraction. This procedure facilitated the reproducibility of results between vessels and animals. Drugs were added to PS in a cumulative manner, with the next concentration being added when a steady-state response had occurred or at a predetermined time, e.g., 5 min. The Ca 2ϩ chelator EGTA (5.0 mM) was applied at the end of the protocols to determine the basal noncontracted tension. Contractile responses to phenylephrine (PE) were normalized to the maximal response above baseline and plotted as log concentration versus the percent response. Relaxation responses were calculated as both percentages of the remaining maximal contraction and percentages of the maximal relaxation. Only one curve was derived for each animal (n ϭ number of animals), and EC 50 and IC50 were determined by linear interpolation between a point just below and just above the 50% response (20) . The percent relaxation was calculated as 100% minus the residual percent contraction in the presence of the maximal concentration (10 M) of ACh, BAY 60-2770, BAY 41-2772, or sodium nitroprusside (SNP).
Circulating Neutrophil Counts
Whole blood was obtained via cardiac puncture after the reperfusion recordings. Samples were diluted 1:20 with 1% gentian violet solution, and total leukocytes were counted by means of a hemocytometer. To obtain the values for neutrophils, a differential count was done on samples stained with Wright Giesma stain, and the product of the total leukocyte count and the percent neutrophils yielded the number of cells per microliter of whole blood.
TNF-␣ Assay
Segments of the jejunum from sham mice or those subjected to the I/R protocols were ground in liquid N2, homogenized in 1 ml lysate buffer [10 mM Tris·HCl (pH 7.4), 250 mM sucrose, 20 mM HEPES, 1 mM EDTA, 1 mM PMSF, and 10 l/ml protease inhibitor cocktail], and then sonicated for 20 s. The homogenate was centrifuged at 12,000 g for 20 min at 4°C, and aliquots of the supernatant were stored at Ϫ70°C. TNF-␣ was measured in duplicate by ELISA (KMC3012, Invitrogen) (27) . The minimum detectable level of TNF-␣ was Յ4 pg/ml, and levels were expressed as picograms per milligram of protein.
Western Blot Analysis
The SMA was dissected free of fat, placed in vials, frozen in liquid N 2, and stored at Ϫ70°C. For each Western blot analysis, three to four SMAs were pooled, ground in liquid N2, and extracted in buffer [125 mM Tris (pH 6.8), 12.5% glycerol, 2% SDS, 50 mM NaF, and trace bromphenol blue]. Proteins were separated by SDS-PAGE. After transfer to a nitrocellulose membrane, blots were blocked with PBS and nonfat milk (5%) and then incubated with antibodies directed against sGC ␣ 1-and sGC ␤1-subunits along with ␤-actin in one set of experiments and against eNOS and ERK1 in a second set of experiments. Membranes were washed in PBS, incubated with horseradish peroxidase-conjugated anti-rabbit or anti-goat antibodies, and developed with commercial chemoluminescence reagents (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The expression of proteins was quantified by scanning densitometry and normalized with respect to ␤-actin or ERK1.
Solutions and Drugs
PS used for the isolated ring experiments had the following composition (in mM): 138 NaCl, 5.0 KCl, 1.5 CaCl2, 1.2 MgCl2, 1.2 NaHPO4, 10 Na-HEPES (pH 7.35), and 11.2 glucose. PE, 5-hydroxytryptamine, SNP, ACh, BAY 41-2272, 5-hydroxydecanoic acid (5-HD), and PAG were purchased from Sigma-Aldrich. Paxilline was purchased from Enzo Life Sciences. Antibodies against eNOS and ERK1 were from BD Transduction Laboratories and Santa Cruz Biotechnology, respectively. Bay 60-2770 was a gift from Bayer Schering Pharma (Wuppertal, Germany). Stock solutions (10 mM) of PE and ACh were prepared in 10 mM ascorbic acid and frozen (Ϫ20°C). SNP (10 mM) was prepared in ascorbic acid and stored at 4°C. BAY compounds (10 mM) and paxilline (5 mg/ml) were dissolved in DMSO and stored at 4 and Ϫ20°C, respectively. PAG (5 mg/ml) was dissolved in DMSO/saline on the day of the experiment, whereas 5-HD was dissolved in saline only. Dilutions of the various drugs were made into the appropriate solvent on the day of the experiment.
Data Analyses
Data are presented as means Ϯ SE. Student's t-test was used to test for differences between group means where one treatment was being evaluated. ANOVA and the Newman-Keuls method applied post hoc were used to evaluate multiple comparisons. P values of Ͻ0.05 were deemed to be significant. Figure 2 , A and B, shows mean values for the numbers of rolling and adherent leukocytes for experimental groups 1-4. After 30 min of reperfusion, significant increases occurred for both measures in WT mice as well as HO-1 Ϫ/Ϫ mice that had not received any BAY compounds. Similar results were also observed at 60 min of reperfusion (data not shown). ANOVA indicated that the rolling leukocyte response to I/R was greater in HO-1 Ϫ/Ϫ mice (P Ͻ 0.02). No significant increases in leukocyte rolling and adhesion occurred in WT and HO-1 Ϫ/Ϫ mice that had been pretreated with BAY compounds at either 10 min or 24 h before the ischemic episode (Fig. 2) . A similar result was observed at 60 min of reperfusion (data not shown). The protective effects of BAY 60-2770 and BAY 41-2272 compounds were similar in both WT and HO-1 Ϫ/Ϫ mice and could be induced by early-phase as well as late-phase preconditioning.
RESULTS
Inflammatory Responses
The dose-dependent effects of Bay 60-2770 were measured during early-phase preconditioning to determine whether an activator of oxidized (heme-free) sGC would be more effective in HO-1 Ϫ/Ϫ mice, a model with reduced antioxidant reserve. As shown in Fig. 3 , A and B, leukocyte rolling in WT mice remained significantly greater than in sham mice after pretreatment with 3 or 10 g/kg BAY 60-2770, whereas leukocyte adhesion remained elevated after pretreatment with 3 g/kg. In sharp contrast, at these doses, leukocyte rolling and adhesion in HO-1 Ϫ/Ϫ mice did not significantly differ from sham levels. Similar results were also observed at 60 min of reperfusion (data not shown). Therefore, the reduced doses of BAY 60-2770 had a greater effect on early-phase preconditioning in HO-1 Ϫ/Ϫ mice than in WT mice. Experimental protocols 5 and 6 ( Fig. 1) were conducted on HO-1 Ϫ/Ϫ mice to evaluate K ϩ channel activation and H 2 S production during late-phase preconditioning with BAY 60-2770. The 10ϫ dose (300 g/kg) was used to insure maximal late-phase preconditioning in this and subsequent experiments. H 2 S production was reported to be an important factor in the protection conveyed by cinaciquat (BAY 58-2667) on I/R injury in the heart (37), whereas K ϩ channel activation has been proposed to be an important downstream effecter for various preconditioning treatments (8, 49) . We used two PAG treatments for the 24-h protocol to insure inhibition of CSE before BAY 60-2770 was administered as well as during I/R and subsequent measures of leukocyte-venule interactions. As shown in Fig. 4 , A and B, in the presence of PAG, the numbers of rolling and adherent leukocytes remained at or below sham levels during 30 min of reperfusion. Similar results were found with paxilline pretreatment (Fig. 4, A and B) . The protocol used for paxilline was identical to that used previously, which has been shown to block late-phase preconditioning with NaHS (49) . Likewise, an inhibitor of mitochondrial K ATP channels, 5-HD (15, 33), did not significantly alter the late-phase protection conveyed by BAY 60-2770 (Fig. 4, A and B) .
Previous measures of sGC in SMAs showed lower levels in HO-1 Ϫ/Ϫ mice than in WT mice (20) . In a separate series, we repeated these measures on WT and HO-1 Ϫ/Ϫ mice pretreated 24 h with BAY 60-2770 (300 g/kg) to determine whether its interaction with sGC might increase levels. As shown in Fig. 5A , the 24-h pretreatment did not increase sGC. Instead, a significant reduction occurred in sGC ␤ 1 -subunits for both groups. The HO-1 Ϫ/Ϫ group also exhibited reduced sGC ␤ 1 -subunits compared with the WT group, consistent with our earlier report (20) .
It has been reported that eNOS may be essential for the late-phase preconditioning induced by ethanol (46) and for the cardioprotection associated with cinaciquat (BAY 58-2667) ) mice (cross-hatched bars). As noted, drugs were applied 10 min or 24 h before the ischemic period, and BAY 60-2770 was given at two doses (30 and 10 ϫ 30 ϭ 300 g/kg). Bars indicate means Ϯ SE; n ϭ 6. *P Ͻ 0.05 compared with the sham-operated (sham) group within each set of mice. (8) . Although sGC levels in SMAs were significantly reduced in HO-1 Ϫ/Ϫ mice compared with WT mice (20) , measures of eNOS levels were equivalent, as shown in Fig. 5B ; hence, eNOS could be a factor in BAY 60-2770-induced preconditioning in WT and HO-1 Ϫ/Ϫ mice. Protocols 1-4 and 6 were repeated on eNOS Ϫ/Ϫ mice to determine whether its expression was required for preconditioning with BAY 60-2770. As shown in Fig. 6 , A and B, leukocyte rolling and adhesion remained near sham levels after early-and late-phase preconditioning. Moreover, treatment of eNOS Ϫ/Ϫ mice with PAG did not alter the late-phase preconditioning response to BAY 60-2770.
Measures of jejunum TNF-␣, as shown in Fig. 7 , were done to determine whether late-phase preconditioning with BAY compounds had an anti-inflammatory effect upstream to the venules. A significant three-to fourfold increase in TNF-␣ occurred after I/R in WT and HO-1 Ϫ/Ϫ mice, whereas the increase in eNOS Ϫ/Ϫ mice was twofold. Pretreatment with both BAY compounds prevented the increase in WT and 
HO-1
Ϫ/Ϫ mice and Bay 60-2770 in eNOS Ϫ/Ϫ mice, similar to leukocyte-endothelium interactions. Also, there was a tendency for HO-1 Ϫ/Ϫ mice to exhibit higher content of TNF-␣ than WT and eNOS Ϫ/Ϫ mice under equivalent conditions. I/R was also associated with increased circulating levels of neutrophils in WT, HO-1 Ϫ/Ϫ , and eNOS Ϫ/Ϫ mice, as shown in Fig. 8 . The response was greatest in HO-1 Ϫ/Ϫ mice. In contrast to the effects on leukocyte-venule interactions and tissue TNF-␣, late-phase preconditioning of WT mice with BAY 41-2272 did not prevent the increase in neutrophils. BAY 60-2770 prevented the increase in both WT and HO-1 Ϫ/Ϫ mice but not in eNOS Ϫ/Ϫ mice. Unlike WT mice, BAY 41-2272 appeared to be effective in HO-1 Ϫ/Ϫ mice. Overall, the pattern of circulating neutrophil changes in response to BAY compounds differed from that for leukocyte-venule interactions. This indicated that mechanisms in addition to a reduction in circulating neutrophils were operative during preconditioning with BAY compounds.
Contractile Responses
The SMA was studied because it is the feeder vessel to the intestine that was subjected to I/R. Measures were made of PE Ϫ/Ϫ mouse type (P Ͻ 0.01) and BAY 60-2770 pretreatment (300 g/kg 24 h, P Ͻ 0.03) with no significant interaction. The expression of the sGC ␣1-subunit exhibited a greater variance, and no significant effects were observed. As shown in B, the expression of eNOS from untreated mice was similar in both groups.
concentration-dependent contractures and subsequent relaxation to agents that directly or indirectly act on sGC. SMAs from all three mouse groups exhibited significant responses to the agents. The IC 50 for ACh was shifted to a higher concentration (lower sensitivity) by I/R in HO-1 Ϫ/Ϫ mice, as was that to BAY 41-2272 in both WT and HO-1 Ϫ/Ϫ mice (Fig. 9A ). I/R had no significant effect on SMAs from eNOS Ϫ/Ϫ mice. It should be noted that sham WT mice exhibited 5-fold greater sensitivity to ACh compared with HO-1 Ϫ/Ϫ and eNOS Ϫ/Ϫ mice and 20-fold lower sensitivity to BAY 60-2770. Combined pretreatment (both early and late) with BAY compounds had significant effects on sensitivity, as shown by the changes in log M 50 (Fig. 9B) . The sensitivity to PE was reduced (positive change) in WT mice, whereas it was unchanged in HO-1
and eNOS Ϫ/Ϫ mice. ACh sensitivity was increased (negative change) in WT and HO-1 Ϫ/Ϫ mice, with the ACh effect being particularly large in HO-1 Ϫ/Ϫ mice, exceeding WT mice by sixfold. The sensitivity to BAY 41-2272 was also increased in these groups. Opposing effects were observed for BAY 60-2770. WT mice exhibited increased sensitivity, whereas HO-1 Ϫ/Ϫ mice showed a decrease. The net effect was that the difference in IC 50 for BAY 60-2770 (Fig. 9A ) was nullified by pretreatment with BAY compounds. eNOS Ϫ/Ϫ mice exhibited no significant changes in sensitivity after pretreatment with BAY compounds. 
B
C h a n g e in s e n s itiv ity Pretreatment with BAY compounds also affected the percent relaxation of the SMA, as shown in Fig. 10 . The relaxation was significantly increased in HO-1 Ϫ/Ϫ mice to all sGC active compounds and to three of four sGC active compounds in WT mice. BAY pretreatments had significantly greater effects on HO-1 Ϫ/Ϫ mice for the three compounds that work via stimulation of reduced sGC. eNOS Ϫ/Ϫ mice exhibited significantly greater (P Ͻ 0.05) relaxation to ACh (68 Ϯ 7%, n ϭ 6) compared with WT mice (40 Ϯ 9%, n ϭ 12). The relaxation of eNOS Ϫ/Ϫ mice to the various agents (Fig. 10) was not significantly affected by pretreatment with BAY compounds.
DISCUSSION
The principle findings of these experiments show that pretreatment with an activator or a stimulator of sGC will convey both early-and late-phase protection from the venular inflammatory response triggered by I/R in WT mice. Moreover, similar protection was observed in HO-1 Ϫ/Ϫ mice, which have reduced antioxidant capacity and develop NO tolerance (20, 22) . The late-phase preconditioning by BAY 60-2770 was retained during blockade of H 2 S synthesis and of paxilline-or 5-HD-sensitive K ϩ channels and in the absence of eNOS. BAY compounds also normalized the sensitivity of SMAs to ACh in HO-1 Ϫ/Ϫ mice. In addition, preconditioning prevented the increase in intestinal TNF-␣ observed in untreated mice that underwent I/R. This effect, which is in tissue upstream to the venules, may also contribute to protecting venules from the inflammatory response.
Leukocyte-Endothelial Interactions
As previously reported, ischemia of the small intestine in WT and HO-1 Ϫ/Ϫ mice was associated with increased leukocyte rolling and adhesion to the venular endothelium within 30 min of reperfusion (48, 49) . Pretreatment with relatively high doses of BAY compounds conveyed protection to both groups, whether given 10 min or 24 h before ischemia (Fig. 2) . Although HO-1 Ϫ/Ϫ mice would be expected to have less sGC in the reduced form and less total content (Fig. 5A ) than WT mice, there appears to be sufficient sGC in reduced and oxidized states (i.e., spare NO receptors) to allow responses to both BAY compounds (20) . When pretreated at 10 min with doses of BAY 60-2770 of Յ10 g/kg (Fig. 3), HO-1 Ϫ/Ϫ mice maintained near sham levels of rolling and adhesion after I/R, whereas WT mice exhibited significant increases. This is consistent with the presence of a higher level of oxidized heme-free sGC in HO-1 Ϫ/Ϫ mice than in WT mice. (See Refs. 10, 24, 28, and 30 for background concerning the highly specific interaction between BAY 58-2667 and BAY 60-2770 with the vacated heme pocket of sGC that occurs after oxidation of the heme Fe 2ϩ to Fe 3ϩ .) This difference in sGC may have persisted after 24 h preconditioning, since treatment with BAY 60-2770 was associated with a reduction in sGC levels in SMAs as well as reduced levels in HO-1 Ϫ/Ϫ mice compared with WT mice (Fig. 5A ). This finding was unexpected in light of an in vitro study (30) showing that BAY 58-2667 prevented an oxidation-induced downregulation of sGC. In that study (30) , rat aortas were maintained in tissue culture for 20 h with 10 M BAY 58-2667 and the oxidant 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ); in contrast, our in vivo protocol used one dose of BAY 60-2770, which would be expected to result in a lower concentration (ϳ1 M) that would fall progressively during 24 h. Also, another in vitro study (23) indicated that simulation of rat aortic sGC with YC-1 for 24 h reduced sGC levels, possibly through an effect of the cGMP pathway on the stability of sGC mRNA. Under our conditions, it appears that early-phase as well as late-phase preconditioning conveyed by BAY 60-2770 occurs through targets of the sGC-cGMP-PKG pathway rather than a major increase in sGC levels. The possibility also exists that the relative balance between reduced and oxidized sGC may be shifted toward the reduced state. Several of these concepts are shown in Fig. 11 as a diagram. Because altered vascular redox regulation is associated with many pathological states (44) , it is anticipated that the use of an activator of oxidized heme-free sGC, such as BAY 58-2667 or BAY 60-2770, would provide the more efficacious approach to activating the sGC-cGMP-PKG pathway.
We also studied the effects of several interventions that have been reported to be effective in blocking preconditioning pathways induced by other agents. As noted above, the BAY compounds were effective in providing early-and late-phase protection in HO-1 Ϫ/Ϫ mice, whereas NaHS did not (48). These observations support the concept that HO-1 expression and activity in the endothelium is an important mediator of the pretreatment with an H 2 S donor. In another study (47) , NaHSinduced preconditioning was found to depend on eNOS, with subsequent production of NO. In the present study (Fig. 4) , the anti-inflammatory effects of sGC-cGMP-PKG signaling occurred downstream and could be initiated by NO as well as other sGC active agents without changes in HO-1 expression. It has been proposed, however, that the increased production of H 2 S in response to BAY 58-2667 (acting similarly to BAY 60-2770) is a necessary step in postischemic myocardial protection (37) . The administration of BAY 58-2667 to mice 30 min before ischemia was associated with an 80% reduction in infarct size 24 h after reperfusion. The reduction in infarct size C h a n g e in R e la x a tio n was blocked entirely when PAG, a CSE inhibitor, was given 30 min before BAY 58-2667. We tested the H 2 S dependence of late-phase protection in HO-1 Ϫ/Ϫ mice, which exhibit a compromised antioxidant capacity. Two PAG treatments (30 min before BAY 60-2770 and 30 min before ischemia) were used with the 24-h preconditioning protocol to ensure that CSE (and additional H 2 S production) would be blocked before the acute effects of BAY 60-2770 and ischemia occurred. Under these conditions, the venules were fully protected from leukocyte rolling and adhesion (Fig. 4 ). It appears that increased H 2 S production may not be required for late-phase preconditioning protection against an early inflammatory response to I/R. This observation does not rule out later consequences of BAY 58-2667 treatment, e.g., tissue infarct size after 24 h, that may be affected by increased CSE activity and the resultant H 2 S as well as other factors, such as shifts in eNOS activity.
It has been reported that the cardioprotection conveyed by BAY 58-2667 (applied during the last 5 min of ischemia) can be blocked by simultaneous treatment with N-nitro-L-arginine methyl ester (8) . Unlike preconditioning with agents that increase PKG activity, they proposed that PKG was active upstream to eNOS and NO production when the conditioning agent was applied during ischemia. We tested the dependence of early-and late-phase preconditioning on eNOS by means of a knockout model. Under these conditions, BAY 60-2770 conveyed protection against the venular inflammatory response (Fig. 6) . It is of further interest that treatment of eNOS Ϫ/Ϫ mice with PAG had no effect on late-phase protection with BAY 60-2770. Future experiments where BAY compounds are given during the last 5-10 min of ischemia should be conducted to determine whether a similar or different series of signals are involved in protection against this inflammatory response. It is important to resolve this issue, since a potential clinical application would involve giving such agents before reestablishing blood flow to an ischemic organ, where the option of giving it before the ischemic episode (as was done in our study) is nonexistent.
Intestinal TNF-␣
In addition to vascular effects, pretreatment with BAY compounds prevented the increase in small intestinal TNF-␣ associated with I/R (Fig. 7) . Since the venules receive blood and extracellular fluid draining from this tissue, reduced TNF-␣ perfusion and extracellular diffusion may have contributed to the reduced leukocyte-endothelial interactions (Fig.  11) . TNF-␣ is synthesized and released from macrophages and parenchymal cells via highly regulated processes that are sensitive to conditions existing during I/R (29) . The role of PKG activation in the regulatory process is not well understood, and comments based on our data would be highly speculative. The presence of TNF-␣ after I/R, however, could be a major factor. For instance, I/R-induced vascular dysfunction in hearts was absent in TNF-␣-deficient mice (14) .
Linkage Between BAY Pretreatments and Reduced Leukocyte-Endothelial Interactions
Extensive literature indicates that the primary effect of BAY compounds is on sGC leading to the production of cGMP (30, 40) . This relation is shown in Fig. 11 . The question arises as to how this translates to the inhibition of leukocyte rolling and adhesion in venules that we observed after I/R in three mouse models. Insights and potential experiments can be derived from the current literature. The process of leukocyte-endothelial interaction after I/R is regarded to occur in several stages (5, 18) . Endothelial cells become "activated" in response to various factors (e.g., ROS, TNF-␣, and ␣-thrombin) released during reperfusion. Part of this process involves receptor-G protein-coupled events, whereas others, e.g., ROS, may have intracellular actions leading to significant elevation of cytosolic Ca 2ϩ (7) . Ca 2ϩ is regarded to be an important cofactor for the fusion of P-selectin storage vesicles with the surface membrane of endothelial cells. Fusion results in the extracellular exposure of the elongated arm of P-selectin, which acts as a receptor for the tethering of leukocytes (5) . This results in leukocyte rolling and primes them for subsequent adhesive arrest. The percentage of cultured endothelial cells that tested positive for Pselectin after an inflammatory stimulus was reduced by half in the presence of BAY 41-2772 (1) . It was also shown that inhibition of the ␣-thrombin-induced Ca 2ϩ signal with a chelator reduced the amount of P-selectin incorporated into the membranes of endothelial cells (7) . Thus, the entry and release of cellular Ca 2ϩ is an important component of P-selectin signaling and may be influenced by cGMP signaling (Fig. 11) .
Extensive literature has established linkages between increases in cGMP, PKG activity, and altered cellular Ca 2ϩ regulation (12) . Phosphorylation of several PKG substrates directly reduces cytosolic Ca 2ϩ during exposure to receptor active agents. The targeted substrates include 1) inositol 1,4,5-trisphosphate receptor-associated proteins, which, in turn, lead to inhibition of Ca 2ϩ release from the endoplasmic reticulum (ER); 2) phospholamban, leading to increased Ca 2ϩ uptake into the ER; and 3) phospholipase C and regulators of G protein signaling, resulting in reduced inositol 1,4,5-trisphosphate production and subsequent Ca 2ϩ release from the ER. The entry of Ca 2ϩ is also inhibited via PKG phosphorylation of transient receptor potential channels, which are particularly important for Ca 2ϩ influx into endothelial cells during activation with agonists (25, 39) . One study (11) demonstrated that an NO donor caused 90% inhibition of the Ca 2ϩ transient induced by ␣-thrombin in endothelial cells, indicating the extent to which activated PKG can maintain Ca 2ϩ at basal levels in the presence of agonists. These effects on Ca 2ϩ are shown in Fig. 11 .
The inhibitory effects of PKG activation on cytosolic Ca 2ϩ may have important consequences in preventing the endothelial dysfunction caused by TNF-␣ released from tissues undergoing I/R (14) . TNF-␣ is regarded to be a major factor during the early inflammatory response in the endothelium and is associated with increased membrane expression of P-selectin (18, 19) . Since this process is Ca 2ϩ dependent (from the discussion above), it would be subject to inhibition by BAY compounds. TNF-␣ is also associated with increased cytosolic phospholipase A 2 activity (cPLA 2 ) and the release of arachidonic acid and its metabolites (2). cPLA 2 contains multiple regulatory sites for Ca 2ϩ as well as phosphorylation that are required for maximal activation (3, 17, 34) . It would be expected that a PKG effect that reduces Ca 2ϩ would prevent full activation of cPLA 2 (Fig. 11) . The importance of TNF-␣-mediated signaling through type 1 receptors and cPLA 2 is underscored by the attenuation of I/R injury in cPLA 2␣ -deficient mice and in TNF-␣ receptor type 1-deficient mice (9, 36) . Therefore, agents such as the BAY compounds used in this study may be particularly useful in preventing early inflammatory responses.
Additional targets for PKG may also be involved in the protection conveyed by BAY compounds. The activity of K ATP and Ca 2ϩ -sensitive K ϩ channels can be increased, whereas that of L-type Ca 2ϩ channels is inhibited (12) . Since K ATP channels are expressed on mitochondria, activation can be involved in protecting against the damaging effects of I/R (8, 21) . These actions may be of additional importance to the dilator responses of arterial smooth muscle, which exhibit high expression of the various K ϩ and Ca 2ϩ channels. Pretreatment with paxilline as well as 5-HD, however, failed to block late-phase preconditioning with BAY 60-2770 (Fig. 4) . Hence, alternate PKG targets (discussed above) may be more relevant to the prevention of I/R induced leukocyte-endothelial interactions in HO-1 Ϫ/Ϫ venules.
Vascular Smooth Muscle Relaxation
The SMA from HO-1 Ϫ/Ϫ exhibited nitrate tolerance of the type previously reported (20) ; moreover, I/R was associated with decreased sensitivity to ACh (Fig. 9A) consistent with a reduced sensitivity of sGC to NO. It should be noted that eNOS expression, a source of NO during ACh stimulation, was similar in WT and HO-1 Ϫ/Ϫ mice (Fig. 5B) . The SMA from eNOS Ϫ/Ϫ mice had a greater relaxation response to ACh than that from WT mice. This was expected from previous reports (4, 42) that showed ACh relaxation of mesenteric arteries was shifted to a greater dependence on EDHF and/or cyclooxygenase products. This shift in regulation may underlie the lack of effect of changes in drug sensitivity and relaxation in SMAs from eNOS Ϫ/Ϫ mice pretreated with BAY compounds (Figs.  9B and 10) .
The heme Fe 2ϩ on sGC is prone to oxidation to Fe 3ϩ under conditions of increased ROS with subsequent loss of sensitivity to NO (20, 31, 44) . Although other antioxidant systems are operative, HO-1 appears to be particularly important for the maintenance of sGC in a reduced NO-sensitive state (Fig. 11) . Caveolin-1 has been shown to act as a platform for the colocalization of sGC, HO-1, and eNOS in endothelial cells (22, 26) . It has been hypothesized that the close proximity of a source of NO and carbon monoxide to sGC would convey a functional advantage. Moreover, the tethering of sGC near a source of antioxidant activity would convey protection from Fe 2ϩ oxidation. Such protection was compromised in pressureoverloaded hearts, which exhibited reduced NO-stimulated sGC activity (41) . The reduction was associated with translocation of sGC from caveolin-3 to cytosolic fractions where oxidation of sGC occurred more readily. As expected, the cGMP response to BAY 60-2770 in the cytosolic fractions remained at near control levels. The sGC heme can be subject to immediate oxidation by micromolar peroxynitrite (a product of NO and O 2 Ϫ ) even in the presence of 5 mM reduced glutathione (13) . BAY 58-2667 and BAY 60-2770 are structurally similar and have been shown to fit into the subsequently vacated heme pocket (28) . In vitro treatment of the rat aorta with BAY 58-2667 under oxidized conditions led to 1) activation of heme-free sGC with subsequent production of cGMP and 2) protection of sGC from ubiquitination and proteasomal degradation (30) . Under our in vivo conditions, it appears that sGC levels were not increased by 24-h pretreatment with a single dose of BAY 60-2770 (Fig. 5A) ; hence, sGC activation with a possible increase in the relative amount of reduced sGC may be the main contributor to the increased sensitivity and relaxation to ACh, BAY 41-2272, and SNP after preconditioning (Figs. 9B and 10) .
The leukocyte-endothelium section emphasized PKG sensitive Ca 2ϩ linkages that also apply to smooth muscle and have been previously reviewed (12, 38) . The increase in SMA sensitivity to ACh and BAY 41-2272 exhibited by both WT and HO-1 Ϫ/Ϫ mice (Fig. 9B) could reflect an increased availability of reduced heme-containing sGC. This would be expected to support the increased relaxation that was observed for NO stimulation (ACh and SNP) as well as stimulation by BAY 41-2272 (Fig. 10) . It is uncertain what mechanisms underlie these increased responses under conditions where sGC levels did not increase. Rather than increase sensitivity, persistent cGMP signaling has been documented to desensitize smooth muscle to NO and other sGC active agents (12) . Much of the focus has been on the role of phosphodiesterases, especially phosphodiesterase 5, in this process (12) , and this is shown in Fig. 11 . "Feedforward" mechanisms have also been suggested to explain some observations of increased sensitivity, but these have not been defined in much detail. H 2 S may also have an important role in preserving cGMP through its action as an antioxidant and as a phosphodiesterase inhibitor (43) , as shown in Fig. 11 .This area of sGC regulation will require further study to determine how preconditioning with BAY compounds can insure a responsive vascular system to an organ affected by an episode of I/R.
Conclusions
A growing body of evidence has indicated that stimulation of the sGC-cGMP-PKG pathway provides significant cardiovascular protection against inflammatory events involving ROS. This pathway has targets that apparently act downstream (or parallel) to eNOS, H 2 S, and some K ϩ channels, which in themselves can also support preconditioning. Among the agents available, activators of sGC (e.g., BAY 58-2667 and BAY 60-2770) are of particular interest in that they preferentially act on oxidized heme-free sGC, which can be elevated under pathological conditions where antioxidant systems are stressed, as in HO-1 Ϫ/Ϫ mice. sGC activation appears to be important for the preservation of nitrate sensitivity in the vascular system and normal vascular responsiveness to endothelial control. Connections need to be established more definitively between the actions of sGC activators and altered immune responses, such as TNF-␣ expression and release. There is much more happening than can be explained by cellular Ca 2ϩ regulation alone. This is an important area to be explored and is highly relevant to developing strategies to minimize the damage done by and during treatment of occlusive vascular disease.
